Could a quick cholesterol shot after a heart attack save lives?
NCT ID NCT07208006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early in the hospital, right after a heart attack, can reduce the chance of another heart attack, stroke, or death over the next year. About 1,500 adults with multiple blocked arteries will be split into two groups: one gets standard care, and the other gets the PCSK9 shot plus standard care. The goal is to see if the early, strong treatment helps stabilize dangerous plaques and prevents future heart problems.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- PCSK9 monoclonal antibody (a type of drug that lowers cholesterol quickly and strongly)
- What this could lead to
- If it works, this could point toward a new standard treatment to prevent repeat heart attacks and strokes in people with multiple blocked arteries.
- What could go wrong
- This is a large but still early-stage trial, and the drug may not reduce heart events more than standard care. It also requires injections and may have side effects like injection-site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,518 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Age ≥18 years. 2. Acute myocardial infarction (AMI) onset within 30 days (first hospitalization with a confirmed diagnosis of STEMI or NSTEMI). 3. Multivessel coronary artery disease; successful percutaneous coronary intervention (PCI) of the culprit lesion in the infarct-related artery (IRA), including stent implantation and/or balloon angioplasty and/or thrombus aspiration. 4. At least one angiographically assessed diameter stenosis ≥50% in a non-infarct-related artery (non-IRA) with a reference vessel diameter ≥2.5 mm. 5. Able to understand and willing to provide written informed consent, comply with prescribed medical therapy, and complete the required follow-up. Exclusion Criteria 1. Cardiogenic shock or severe heart failure (Killip class IV). 2. Serum creatinine \>150 μmol/L or glomerular filtration rate (GFR) \<45 mL/min/1.73 m² calculated by the Cockcroft-Gault equation. 3. Known or suspected infective endocarditis or active systemic infection. 4. Clinically significant coagulation abnormalities, or anticipated inability to tolerate long-term antiplatelet therapy. 5. Pregnant or breastfeeding women, women planning pregnancy within 1 year, or those unwilling to use effective contraception. 6. Expected survival \<1 year. 7. Allergy to iodinated contrast media. 8. Prior coronary artery bypass grafting (CABG). 9. Participation in another clinical trial within 3 months before enrollment, or current participation in another drug/device clinical trial without having reached its primary endpoint. 10. Coronary angiography-based exclusion criteria: 10.1 Non-IRA lesion with visually estimated diameter stenosis \>90% and TIMI flow ≤2; 10.2 Complex coronary artery disease requiring CABG; 10.3 Angiography unable to clearly identify the infarct-related artery or non-infarct-related arteries.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A temporary wire that keeps hearts beating on cue
- AI may spot deadly heart rhythms before they strike
- Antioxidant infusion may shield the heart from reperfusion injury
- Can a temporary heart pump save more lives in cardiogenic shock?
- Can a Community-Based rehab program boost heart recovery after a first attack?
- AI on a simple ECG: a new way to gauge heart attack severity?